{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-001222","form_type":"8-K","ticker":"HBIO","cik":"0001123494","company_name":"HARVARD BIOSCIENCE INC","filed_at":"2024-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.450200+00:00","generated_at":"2026-06-05T01:08:41.637351+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Harvard Bioscience Q4 2023 revenue $28.2M, guides 2024 flat-to-modest growth, margin improvement","bullets":["Q4 revenue $28.2M, down 1% YoY; gross margin 58.0%, up 230 bps YoY.","Q4 net loss $1.8M, adj. EPS $0.04; adj. EBITDA $3.6M (13% margin).","FY2023 revenue $112.3M, down 1% YoY; adj. EBITDA $14.6M (13% vs 9.6% prior year).","Debt reduced by $10.5M in 2023; net leverage improved from 4.0x to 2.3x.","2024 guidance: flat to modest revenue growth; gross margin ~60%; adj. EBITDA margin mid-teens."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-001222","json":"https://secwatch.observer/filing/0001171843-24-001222.json","markdown":"https://secwatch.observer/filing/0001171843-24-001222.md","text":"https://secwatch.observer/filing/0001171843-24-001222.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1123494/000117184324001222/0001171843-24-001222-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1123494/000117184324001222/f8k_030624.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T01:08:41.637351+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0893e4243aa992957e0d640312b1d16ca8809812","claim":"HARVARD BIOSCIENCE INC reported the fourth quarter ended December 31, 2023 results: revenue $28.2 million, net income $(1.8) million, EPS $(0.04) per diluted share.","evidence_excerpt":"a filing. --- EX-99.1 (EXHIBIT 99.1) --- EX-99.1 2 exh_991.htm EXHIBIT 99.1 Exhibit 99.1 Harvard Bioscience Announces Fourth Quarter 2023 Financial Results · Q4 Revenues of $28.2 million · Q4 Gross Margin of 58.0% (230 bps year-over-year improvement) · Q4 operating income of $0.3 million, adjusted operating income of $3.3 million · Strong operating cash flow","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1123494/000117184324001222/0001171843-24-001222-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2023"},{"label":"Revenue","value":"$28.2 million"},{"label":"Net income","value":"$(1.8) million"},{"label":"EPS","value":"$(0.04) per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"81c58ef5f1fe189f6ec4ba10d73bd05446256f2f","claim":"HARVARD BIOSCIENCE INC reported the fiscal year ended December 31, 2023 results: revenue $112.3 million, net income $(3.4) million, EPS $(0.08) per diluted share. Guidance initiated.","evidence_excerpt":"in the same period last year. Debt was reduced by $2.3 million during the quarter. Year Ended December 31, 2023 Highlights For the year ended December 31, 2023, revenues were $112.3 million, compared to $113.3 million in the same period a year ago. Revenues for the year include a net reduction of $5.0 million from discontinued products compared to 2022. Gross margin","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1123494/000117184324001222/0001171843-24-001222-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2023"},{"label":"Revenue","value":"$112.3 million"},{"label":"Net income","value":"$(3.4) million"},{"label":"EPS","value":"$(0.08) per diluted share"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}